Search
tasimelteon (VEC-162)
Indications:
- transient insomnia due to shift work or jet lag
- sleep-wake disorder in the blind [2]
Dosage: 10, 20, 50, or 100 mg PO QHS
Pharmacokinetics:
- elimination 1/2life 1.3 hours
Mechanism of action:
- melatonin agonist
General
receptor agonist
sleeping pill
References
- Rajaratnam SMW et al
Melatonin agonist tasimelteon (VEC-162) for transient
insomnia after sleep-time shift: Two randomised controlled
multicentre trials.
Lancet 2009 Feb 7; 373:482.
PMID: 19054552
- Cardinali DP and Golombek DA.
Let there be sleep - On time.
Lancet 2009 Feb 7; 373:439.
PMID: 19054553
- FDA News Release: Jan. 31, 2014
FDA approves Hetlioz: first treatment for non-24 hour
sleep-wake disorder in blind individuals.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm384092.htm